158 related articles for article (PubMed ID: 18611067)
1. Long-acting GLP-1 analogs for the treatment of type 2 diabetes mellitus.
Vilsbøll T; Knop FK
BioDrugs; 2008; 22(4):251-7. PubMed ID: 18611067
[TBL] [Abstract][Full Text] [Related]
2. Incretin-based therapy of type 2 diabetes mellitus.
Knop FK; Vilsbøll T; Holst JJ
Curr Protein Pept Sci; 2009 Feb; 10(1):46-55. PubMed ID: 19275672
[TBL] [Abstract][Full Text] [Related]
3. Incretin-based therapy and type 2 diabetes.
Hare KJ; Knop FK
Vitam Horm; 2010; 84():389-413. PubMed ID: 21094909
[TBL] [Abstract][Full Text] [Related]
4. The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes.
Drucker DJ; Nauck MA
Lancet; 2006 Nov; 368(9548):1696-705. PubMed ID: 17098089
[TBL] [Abstract][Full Text] [Related]
5. Clinical efficacy and safety of once-weekly glucagon-like peptide-1 agonists in development for treatment of type 2 diabetes mellitus in adults.
Tzefos M; Harris K; Brackett A
Ann Pharmacother; 2012 Jan; 46(1):68-78. PubMed ID: 22232377
[TBL] [Abstract][Full Text] [Related]
6. Incretin mimetics and DPP-4 inhibitors: new approach to treatment of type 2 diabetes mellitus.
Siddiqui NI
Mymensingh Med J; 2009 Jan; 18(1):113-24. PubMed ID: 19182763
[TBL] [Abstract][Full Text] [Related]
7. Glucagon-like peptide-1 analogues for Type 2 diabetes mellitus: current and emerging agents.
Gallwitz B
Drugs; 2011 Sep; 71(13):1675-88. PubMed ID: 21902291
[TBL] [Abstract][Full Text] [Related]
8. The spectrum of antidiabetic actions of GLP-1 in patients with diabetes.
Vilsbøll T; Holst JJ; Knop FK
Best Pract Res Clin Endocrinol Metab; 2009 Aug; 23(4):453-62. PubMed ID: 19748063
[TBL] [Abstract][Full Text] [Related]
9. Therapies for the treatment of type 2 diabetes mellitus based on incretin action.
Gallwitz B
Minerva Endocrinol; 2006 Jun; 31(2):133-47. PubMed ID: 16682937
[TBL] [Abstract][Full Text] [Related]
10. Emerging GLP-1 receptor agonists.
Lund A; Knop FK; Vilsbøll T
Expert Opin Emerg Drugs; 2011 Dec; 16(4):607-18. PubMed ID: 21905764
[TBL] [Abstract][Full Text] [Related]
11. Incretins and their role in the management of diabetes.
Frias JP; Edelman SV
Curr Opin Endocrinol Diabetes Obes; 2007 Aug; 14(4):269-76. PubMed ID: 17940451
[TBL] [Abstract][Full Text] [Related]
12. Focus on incretin-based therapies: targeting the core defects of type 2 diabetes.
Jellinger PS
Postgrad Med; 2011 Jan; 123(1):53-65. PubMed ID: 21293084
[TBL] [Abstract][Full Text] [Related]
13. Emerging incretin based therapies for type 2 diabetes: incretin mimetics and DPP-4 inhibitors.
Stonehouse A; Okerson T; Kendall D; Maggs D
Curr Diabetes Rev; 2008 May; 4(2):101-9. PubMed ID: 18473757
[TBL] [Abstract][Full Text] [Related]
14. Early use of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) in type 2 diabetes.
Ross SA; Ballantine J
Curr Med Res Opin; 2013 Dec; 29(12):1617-26. PubMed ID: 23971789
[TBL] [Abstract][Full Text] [Related]
15. Incretin hormone mimetics and analogues in diabetes therapeutics.
Green BD; Flatt PR
Best Pract Res Clin Endocrinol Metab; 2007 Dec; 21(4):497-516. PubMed ID: 18054732
[TBL] [Abstract][Full Text] [Related]
16. The effects of glucagon-like peptide-1 on the beta cell.
Vilsbøll T
Diabetes Obes Metab; 2009 Dec; 11 Suppl 3():11-8. PubMed ID: 19878257
[TBL] [Abstract][Full Text] [Related]
17. Treatment of type 2 diabetes with glucagon-like peptide-1 receptor agonists.
Hansen KB; Knop FK; Holst JJ; Vilsbøll T
Int J Clin Pract; 2009 Aug; 63(8):1154-60. PubMed ID: 19624785
[TBL] [Abstract][Full Text] [Related]
18. Comparison of liraglutide versus other incretin-related anti-hyperglycaemic agents.
Blonde L; Montanya E
Diabetes Obes Metab; 2012 Apr; 14 Suppl 2():20-32. PubMed ID: 22405266
[TBL] [Abstract][Full Text] [Related]
19. Incretin therapies in the management of elderly patients with type 2 diabetes mellitus.
Bourdel-Marchasson I; Schweizer A; Dejager S
Hosp Pract (1995); 2011 Feb; 39(1):7-21. PubMed ID: 21441754
[TBL] [Abstract][Full Text] [Related]
20. Effects of incretin hormones on beta-cell mass and function, body weight, and hepatic and myocardial function.
Mudaliar S; Henry RR
Am J Med; 2010 Mar; 123(3 Suppl):S19-27. PubMed ID: 20206728
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
